Miyakawa T, Minamisawa K, Yamada Y, Sasaki O, Fujiki Y, Tochikubo O, Ishii M
Second Department of Internal Medicine, Yokohama City University of Medicine, Japan.
Am J Hypertens. 1991 Jan;4(1 Pt 2):29S-37S. doi: 10.1093/ajh/4.1.29s.
In order to investigate the effect of delapril, a new angiotensin converting enzyme inhibitor, on the diurnal variation of arterial pressure in patients with essential hypertension, this study examined 24 h arterial pressure using an indirect or a direct monitoring system. When the effect of twice-a-day administration of delapril at daily doses of 30 to 90 mg was examined using the indirect monitoring system in 12 outpatients, delapril decreased systolic and diastolic arterial pressures significantly only at limited points during the day. However, each of the averaged 24 h daytime and nighttime arterial pressures showed significant reductions. The 24 h intraarterial pressure monitoring demonstrated that delapril decreased systolic and diastolic arterial pressure at most of the measurement points. The arterial pressure reductions during daytime and nighttime were not significantly different, that is, there was no excessive reduction in nighttime arterial pressure. Heart rate and its variability were virtually unaffected by the delapril treatment in either monitoring study. No adverse reactions were observed in the indirect or direct monitoring studies. Thus, it is concluded that twice-a-day administration of delapril at daily doses of 30 to 90 mg brings about a safe and stable antihypertensive effect, without affecting the diurnal variation of arterial pressure.
为研究新型血管紧张素转换酶抑制剂地拉普利对原发性高血压患者动脉血压昼夜变化的影响，本研究采用间接或直接监测系统检测了24小时动脉血压。在12名门诊患者中，使用间接监测系统检测每日剂量为30至90毫克、每日两次服用地拉普利的效果时，地拉普利仅在一天中的有限时间点显著降低了收缩压和舒张压。然而，24小时日间和夜间平均动脉血压均显著降低。24小时动脉内血压监测表明，地拉普利在大多数测量点均降低了收缩压和舒张压。白天和夜间的动脉血压降低无显著差异，即夜间动脉血压无过度降低。在两项监测研究中，心率及其变异性实际上均未受到地拉普利治疗的影响。在间接或直接监测研究中均未观察到不良反应。因此，得出结论：每日剂量为30至90毫克、每日两次服用地拉普利可产生安全稳定的降压效果，且不影响动脉血压的昼夜变化。
